In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) for its chimeric antigen receptor T cell (CAR T) therapy, Yescarta (axicabtagene ciloleucel). This new therapy is now approved for adult patients in the United States with relapsed or refractory large B-cell lymphoma who have previously undergone at least two lines of systemic therapy.

Specifics of the Yescarta Approval

Yescarta is now available for treating patients with several subtypes of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). However, it is important to note that Yescarta is not indicated for patients with primary central nervous system lymphatic cancer.

Revolutionizing Cancer Treatment

CAR T therapy, a groundbreaking approach in blood cancer treatment, involves reengineering a patient’s own T cells to target and kill cancer cells. This personalized therapy is tailored for each individual patient, making it a novel treatment option in the oncology field. Frederick L. Locke, Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, emphasized the impressive results of CAR T therapy, noting that many patients have achieved remission for months after failing to respond to traditional treatments like chemotherapy.

Corporate Vision and Future Prospects

David Chang, Worldwide Head of Research and Development and Chief Medical Officer at Kite, highlighted the transformative potential of engineered cell therapies like Yescarta. He stated, “Together, Gilead and Kite will accelerate studies of CAR T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors, aiming to benefit patients with diverse cancers in this new era of personalized cancer therapy.”

Manufacturing and Pricing

Following its FDA approval, Yescarta will be manufactured at Kite Pharma’s facility in El Segundo, California. The drug is priced at $373,000 in the United States, reflecting the complex manufacturing process and the significant therapeutic benefits it offers.

Industry and Patient Advocacy Group Reactions

The approval of Yescarta has been met with enthusiasm from the medical community and patient advocacy groups. Louis J. DeGennaro, PhD, President and CEO of The Leukemia & Lymphoma Society, commented on the pivotal role of CAR T therapy in providing a new treatment option for patients facing a dire prognosis after exhausting other available treatments. His organization is proud to have supported the development of this innovative therapy, recognizing its potential early in its development.

  cancer therapy, CAR-T therapy, FDA approval, Gilead Sciences, Kite Car T therapy Yescarta, Kite Pharma, lymphatic cancer, Lymphoma, lymphoma drug, lymphoma treatment, US FDA, USA, Yescarta